Compare CSL & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSL | BMRN |
|---|---|---|
| Founded | 1917 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 12.3B |
| IPO Year | 1994 | 1999 |
| Metric | CSL | BMRN |
|---|---|---|
| Price | $333.29 | $54.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 28 |
| Target Price | ★ $398.25 | $91.59 |
| AVG Volume (30 Days) | 430.6K | ★ 2.1M |
| Earning Date | 10-28-2026 | 10-30-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.37 | 0.77 |
| Revenue | ★ $5,003,600,000.00 | $1,313,646,000.00 |
| Revenue This Year | $4.77 | $21.45 |
| Revenue Next Year | $4.97 | $14.57 |
| P/E Ratio | ★ $35.80 | $72.72 |
| Revenue Growth | 9.08 | ★ 17.62 |
| 52 Week Low | $293.43 | $49.26 |
| 52 Week High | $432.91 | $70.98 |
| Indicator | CSL | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 31.38 |
| Support Level | $320.15 | $53.61 |
| Resistance Level | $334.46 | $57.95 |
| Average True Range (ATR) | 9.19 | 1.43 |
| MACD | 2.24 | -0.11 |
| Stochastic Oscillator | 68.82 | 11.21 |
Carlisle Companies Inc is a holding company that manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. It operates through two segments: Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The majority of revenue comes from Carlisle Construction Materials, and more than half of total revenue is earned in the United States. Carlisle Construction Materials produces premium single-ply roofing products and warranted roof systems, including EPDM, TPO, PVC membrane, and polyiso insulation. Carlisle Weatherproofing Technologies produces building envelope solutions, including waterproofing, moisture protection products, air/vapor barriers, and spray polyurethane foam systems.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.